Search

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Accelerating Reliable Pharmaceutical Manufacturing for Japan & Global Markets

Meet Aragen Life Sciences at CPHI Japan 2026 | East Hall 2-2C26

Date: April 21-23, 2026 | Location: Tokyo, Japan

Empowering Japanese Pharma with Integrated CRDMO Solutions

Seamless, dual-continent support to accelerate your pipeline from discovery to market.

Integrated CRDMO Across Modalities

  • Small Molecules: End-to-end development and manufacturing in India/US for DS-DP execution (oligonucleotides, peptides, ADC payloads/linkers, mRNA/LNP, HPAPIs, flow chemistry and complex chemistries).
  • Biologics: Full discovery-to-GMP services—upstream, downstream, analytics—with DS-DP readiness (mAbs, bispecifics, ADCs, mRNA-based, vaccines).

Innovation & Future-Ready Capabilities

  • New GMP biologics facility built to global standards for next-generation therapies.
  • AI-driven manufacturing for superior consistency and efficiency.
  • Japan-optimized processes meeting PMDA quality, safety, and regulatory needs.

Dual-Continent Edge for Japanese Clients: 6 World-Class Global Sites

  • India/US operations ensure business continuity, resilient supply chains, and risk mitigation—vital post-pandemic.
  • Scalable capacity from development to commercial scale, no partner switches.

Proven Global Trust

  • 25+ years of excellence in small molecules and biologics.
  • 400+ clients, including Top 10 pharma.
  • Spotless inspections (PMDA, FDA, EMA) for seamless Japan/global supply.

Meet us at CPHI Japan 2026 | East Hall 2-2C26

50+ Japan-Focused Programs Supported

Supporting large pharma and small biotech with PMDA-certified expertise.

  • Deep understanding of PMDA expectations, ensuring high safety, compliance, and alignment with Japanese regulatory standards throughout the development lifecycle.
  • Flexible support for Japan‑specific regulatory documentation, including dossier components, data formatting, and review‑driven updates.
  • Experience collaborating with Japan‑based sponsors across development and manufacturing programs, ensuring reliable & timebound project execution.
  • Aligned to Japanese Business Culture – Professional, respectful communication with a commitment to Monozukuri principles of precision and craftsmanship.

Aragen CRDMO that can assure Japan‑grade quality/compliance, handle complex modalities (biologics, APIs, advanced therapies), and be a long‑term, culturally aligned partner with reliable cost, supply, and innovation capability.

Aragen’s Core Strength

Next-Gen Modalities
  • Oligonucleotides (DNA/RNA)
    • Solid-phase phosphoramidite synthesis; purification, analytics, impurity mapping
  • Peptides
    • SPPS & hybrid routes; complex modifications & conjugation
  • ADCs
    • Payload synthesis, linker chemistries, conjugation development; DAR control & analytics
  • mRNA & LNP Support
    • Enzymatic synthesis, capping, purification; prototype LNP formulation
Process Development & Scale-Up
  • Route scouting and process optimization
  • Impurity profiling and control strategies
  • Scalable processes from gram scale to commercial volumes
  • Cost-effective and robust process design
Small Molecule API Manufacturing
  • Clinical to commercial API manufacturing
  • Multi-purpose and dedicated manufacturing lines
  • Expertise in complex, multi-step synthesis
  • Long-term commercial supply support
High-Potency & Complex Chemistry
  • High-potency API (HPAPI) manufacturing
  • Controlled containment and safety systems
  • Expertise in challenging and specialty chemistries
Late-Stage & Commercial Manufacturing Support
  • Technology transfer from development to commercial scale
  • Process validation and PPQ support
  • Lifecycle management and supply planning
  • Reliable long-term manufacturing partnerships
Analytical Development & Quality Control
  • Analytical method development and validation
  • Stability studies and impurity characterization
  • In-process controls and release testing
  • Strong data integrity and compliance systems
Regulatory & Compliance Excellence
  • Regulatory-ready documentation and DMF support
  • Experience with PMDA, US FDA, EMA, and global agencies
  • Inspection readiness and audit management
  • Ongoing compliance and lifecycle support
Supply Chain Reliability & Business Continuity
  • Dual sourcing and risk mitigation strategies
  • Vendor qualification and raw material sourcing
  • Inventory planning and supply continuity programs
  • Business continuity and disaster recovery planning
Sustainability & Responsible Manufacturing
  • Green chemistry and waste reduction initiatives
  • Energy-efficient manufacturing practices
  • Responsible sourcing and continuous improvement

Walk-ins are welcome, but if you’d prefer to schedule a meeting, please fill in your details to secure a slot.
We look forward to seeing you at the show and discussing how we can support your journey from development to market!
Meet us at CPHI Japan 2026 | East Hall 2-2C26

Building a Resilient & Sustainable Supply Chain

At Aragen, we’re redefining pharma supply chain excellence with a focus on resilience, sustainability, and digital innovation to ensure your molecules reach patients reliably and responsibly.

...

Hyper-Local & Diversified Sourcing

  • 42% of sourcing is hyper-local (within 200 km)
  • Reduced import dependency from ~60% to ~10% in five years
  • 54% supplier diversity with robust performance tracking

94%

On-time deliveries

...

Sustainability at the Core

  • EcoVadis score of 80 (top 1% globally)
  • CDP 2024 A-List for supplier engagement
  • SAF adoption and green fuel logistics expansion
  • Scorecard-based assessment for partners and internal teams

1400+

Global vendor base

...

Digitally-driven Efficiency

  • Fully digitalized source-to-pay (SAP ARIBA & S4 HANA)
  • AI-enabled sourcing and RPA-automated workflows
  • Real-time shipment tracking (inbound & outbound)
  • E-auctions and global compliance screening

25%

TAT reduction in last 3 years

...

Global Coordination Advantage

  • US time zone operations for seamless India–US flow
  • EOU & SEZ benefits for agile, cost-effective delivery
  • Strategic global logistics for supply continuity

105,500

sq. ft. storage space across 5 sites

Join us at CPHI Japan, 2026 to discover how Aragen’s resilient supply chain accelerates your pharma programs, from molecule to market.

Certifications & Sustainability Commitment

Aragen is committed to sustainable and responsible business practices

img

Aragen’s Leadership Presence at CPHI

Meet our team of experts who will be present at CPHI Japan 2026. Connect with us to discuss your drug development challenges.

img

Ashu Tandon

Chief Commercial Officer

img

Aniel Khubchandani

CEO, Development & Manufacturing Solutions

img

Jayadeva Sajankila

VP & Head, Chemical Development Solutions

img

Takahiro Kuno

Senior Director & Head, Business Development, JAPAC

img

Rahul Verma

DGM, Business Development, Biologics

Our Growth Journey

From humble beginnings to a global leader in life sciences.

2001
G V Sanjay Reddy establishes GVK BIO as an Informatics Company, on 2nd April 2001, in Hyderabad, India.
The Company expands into Chemistry Services and signs first FTE contract.
2002
2004
DS Brar joins as Co-Promoter and Chairman
Clinical Pharmacology operations begin.
Manufacturing Unit in Nacharam, Hyderabad (named Indigent Laboratories) is acquired, which eventually expands into an integrated R&D Campus for Discovery, Development and Manufacturing Solutionsr
2005
2006
Biology Services added to solutions offering
Wyeth-dedicated Discovery Chemistry Research Center inaugurated
Manni Kantipudi joins as President (now, Director and CEO)
Sequoia Capital invests in GVK BIO
2007
2008
First Integrated Discovery Program begins
Fine Chemical Development added to the portfolio
Nacharam Vivarium receives AAALAC accreditation
Chemistry, Biology and Integrated Discovery Services expand to more therapeutic areas
2010
2012
India’s largest Isotope Labeling Facility established in Hyderabad
Expansion into Early Development and Scale-up
Inogent Manufacturing Facility receives PMDA approval
Inogent Manufacturing Facility receives USFDA, EU and KFDA approval
2013
2014
GVK BIO acquires Aargeen Bioscience Inc., a US-based preclinical CRO specializing in high value biologics services.
Second R&D Campus inaugurated at Mallapur, Hyderabad. Discovery and Development operations commence.
Formulation Development Labs established in Bengaluru, India.
Aragen Bioscience opens a new vivarium in Morgan Hill, CA
GVK Informatics spins off into an independent entity, Excelra – a Data Structuring and Analytical Solutions Company
ChrysCapital invests in GVK BIO
GVK BIO establishes its third R&D Campus in Bengaluru; Chemistry operations begin
2016
2017
Fine Chemical Manufacturing Plant set up in Hyderabad
Aragen’s US Bioscience vivarium receives AAALAC accreditation
eCule, India’s first mobile app for Discovery Solutions, launched
Inogent Laboratories merges with GVK BIO
Second Manufacturing Facility at Visakhapatnam, India commences production
Analytical Development Labs inaugurated at Mallapur R&D
2018
2019
Aragen Bioscience expands biologics labs on its California campus
Formulation Development Center added to Mallapur R&D Campus
GVK BIO becomes a Great Place to Work–Certified™ organization
Company receives the Best-of-Breed COVID Champion Award from National HR Development Network, in recognition of exemplary work during the pandemic
GVK BIO wins Asia’s Best Employer Brand Award from World HRD Congres
2020
2021
GVK BIO is rebranded Aragen in May, 2021
Goldman Sachs invests in Aragen Discovery Services at Mallapur R&D Campus expand to include a state-of-the-art Compound Management Unit
Certified as Great Place to Work for second consecutive year for High-Trust, High-Performance Culture™
Aragen acquires Intuxe
Aragen wins ‘CEO of the Year’ at the prestigious CPHI Pharma Awards 2022 R&D facility commissioned at Vishakhapatnam
Aragen’s Vivarium in Bengaluru facility registered with the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA)
Aragen becomes an Associate member of Pharmaceutical Supply Chain Initiative
Great Place to Work certification for third consecutive year
2022
2023
Great Place to Work certification for 4th consecutive year
Aragen’s Bangalore vivarium facility receives AAALAC accreditation
Aragen commissions state-of-the-art Formulations Manufacturing Facility in Hyderabad, India
Aragen begins setting up a $30 million bio-manufacturing site in India
Silver Medal in the EcoVadis Sustainability rating
First phase of Biologics manufacturing facility is operationalized in Bengaluru, India
A ₹2000 Cr expansion plan over next five years announced Great Place to Work certification for fifth consecutive year
2024
2025
Successful qualification and commissioning of our advanced biologics GMP manufacturing facility in Bangalore, India.
Achieved Great Place to Work® certification for the 6th consecutive year.
Awarded the Platinum Medal in the EcoVadis Sustainability Rating.
Recognized among India’s Top 25 Best Workplaces™ in Pharmaceuticals, Healthcare, and Biotech for the 5th consecutive year.
Commissioned a state-of-the-art Process R&D Lab with Smart Lab Industry 4.0 integration in Hyderabad, India.
2026

Unlock the Future of Drug Development with Aragen

Meet us at CPHI Japan 2026 | East Hall 2-2C26

Discover how Aragen, a global CRDMO leader, is accelerating pharmaceutical innovation—from molecule to market. Whether you’re a biotech startup or a global pharma, we provide end-to-end support across the drug development lifecycle.

Your Science. Our Solutions.

Let’s Innovate Together

Contact us now

Feel free to email us at info@aragen.com or fill out the contact form to discuss how we can accelerate your program from concept to commercial.

Why Meet Aragen at CPHI Japan 2026

At Aragen, our digital ecosystem seamlessly integrates cutting-edge technologies with human creativity and expertise to accelerate drug discovery, development, and manufacturing. We focus on empowering people with intelligent tools to deliver agile, transparent, and quality-driven solutions across the pharma value chain.

  • Evaluate a trusted global CRDMO partner.
  • Discuss Japan market entry or expansion strategies
  • Strengthen manufacturing and supply chain resilience.
  • Connect directly with scientific and business leaders

Meet us at CPHI Japan 2026 | East Hall 2-2C26